Advances in the treatment of type 2 diabetes: impact of dulaglutide

Advances in the treatment of type 2 diabetes: impact of dulaglutide

Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-...

Full description

Bibliographic Details
Main Authors:	Thompson AM, Trujillo JM
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	dulaglutide GLP-1 receptor agonist T2D
Online Access:	https://www.dovepress.com/advances-in-the-treatment-of-type-2-diabetes-impact-of-dulaglutide-peer-reviewed-article-DMSO

Similar Items

Exacerbation of atrial fibrillation related to dulaglutide use
by: Jayden Lee, et al.
Published: (2021-05-01)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
by: Hisayuki Katsuyama, et al.
Published: (2023-03-01)

Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia
by: Mashael Saad Albargawi, et al.
Published: (2024-05-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
by: Angela Dardano, et al.
Published: (2022-02-01)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
by: Hwi Seung Kim, et al.
Published: (2022-10-01)

Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
by: Sohail Bade, et al.
Published: (2024-09-01)

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature
by: Benedetta Sonego, et al.
Published: (2023-06-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis
by: Emiko Otsuka, et al.
Published: (2024-05-01)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024-08-01)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide
by: Toshitaka Sawamura, et al.
Published: (2022-02-01)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
by: Youngsook Kim, et al.
Published: (2022-06-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis
by: Daisuke Ugamura, et al.
Published: (2022-06-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
by: Lyndon Marc Evans, et al.
Published: (2021-07-01)

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
by: Dandan Xie, et al.
Published: (2022-10-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
by: Antonino Tuttolomondo, et al.
Published: (2021-01-01)

Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study
by: Rina Chin, et al.
Published: (2023-02-01)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
by: Giulia Di Dalmazi, et al.
Published: (2022-07-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
by: Hwi Seung Kim, et al.
Published: (2021-11-01)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
by: Manige Konig, et al.
Published: (2021-09-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
by: Jhih-Wei Dai, et al.
Published: (2024-11-01)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
by: Kugler AJ, et al.
Published: (2018-05-01)

The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
by: Agata Juda, et al.
Published: (2022-11-01)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
by: Yu Su, et al.
Published: (2023-01-01)

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III study
by: Li Xin Shi, et al.
Published: (2020-01-01)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024-03-01)

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
by: Keith C. Ferdinand, et al.
Published: (2023-03-01)

Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India
by: Jasjeet S Wasir, et al.
Published: (2018-01-01)

Mode of administration of dulaglutide: implications for treatment adherence
by: Amblee A
Published: (2016-06-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
by: S. Ghosal, et al.
Published: (2018-05-01)